The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
Cidara Therapeutics Begins Concurrent Common, Preferred Stock Offering, No Size Disclosed
Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it has commenced
Aegis Capital Maintains Buy on Cidara Therapeutics, Lowers Price Target to $8
Aegis Capital analyst Nathan Weinstein maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy and lowers the price target from $9 to $8.
WBB Securities Upgrades Cidara Therapeutics to Strong Buy
WBB Securities analyst Steve Brozak upgrades Cidara Therapeutics (NASDAQ:CDTX) from Buy to Strong Buy.
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Cidara Therapeutics Q2 EPS $0.18 Up From $(0.45) YoY, Sales $32.90M Up From $3.39M YoY
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly earnings of $0.18 per share. This is a 140 percent increase over losses of $(0.45) per share from the same period last year. The company reported $32.90 million in
Cidara Therapeutics Files For U.S. Patent Titled ‘COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS’
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=6878&p=138&f=G&l=50&d=PG01&S1=20210729.PD.&OS=PD/20210729&RS=PD/20210729
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)